# Committee on Energy and Commerce
## U.S. House of Representatives
**Witness Disclosure Requirement - "Truth in Testimony"**
**Required by House Rule XI, Clause 2(g)(5)**

| | | | |
|---|---|---|---|
| 1. **Your Name:** Elizabeth Jungman | | | |
| 2. **Your Title:** Director, Public Health Programs | | | |
| 3. **The Entity(ies) You are Representing:** The Pew Charitable Trusts | | | |
| 4. **Are you testifying on behalf of the Federal, or a State or local government entity?** | Yes | No<br>X | |
| 5. **Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.**<br><br>None. | | | |
| 6. **Please attach your curriculum vitae to your completed disclosure form.**<br><br>Please see attachment. | | | |

**Signature:** [redacted] **Date:** 1/25/2018

# Elizabeth Jungman, J.D., M.P.H.

## Experience

**THE PEW CHARITABLE TRUSTS** Washington, DC
*Director, Public Health Programs* (November 2014-present)
*Director, Drug Safety and Innovation* (January 2014-October 2014)

- Responsible for directing public health projects at Pew, including teams focused on drug safety, antibiotics, and health care products. Oversee policy experts, scientists and advocates to ensure the effective execution of programmatic goals, including research and analysis, policy development, communications and outreach activities.
- Direct a major Pew initiative to address the growing threat of antibiotic resistance by promoting policies to improve stewardship in human health and agriculture, and facilitate the development of new antibiotics.
- Direct work to protect consumers from substandard, counterfeit and adulterated medicines through stronger quality standards and oversight of drug manufacturing and drug compounding.
- Launched a new initiative focused on Food and Drug Administration policy, including dietary supplements, over-the-counter drug products, drug promotion, and other FDA topics.
- Began a new project to utilize federal and state policy levers to reduce the serious health and economic consequences of prescription drug abuse; two years later launched expansion of that work to support evidence-based treatment options, including medication-assisted therapies (through August 2016).
- Represent Pew in public forums, external stakeholder meetings, and in legislative proceedings. Develop and maintain relationships with outside stakeholder organizations.
- Serve as a media resource for public health projects; quoted in national (*e.g.* USA Today, Politico, National Geographic, STAT, Newsday), scientific (Nature News), and trade (*e.g.* FDA News, CQ RollCall, Pink Sheet, Pharmacy Practice News) publications; interviewed on radio (*The Diane Rehm Show*, NPR's *Marketplace*, PBS's WTTW, NPR's KMUW, Iowa Public Radio) and television (*The Dr. Oz Show*).

**U.S. SENATE COMMITTEE ON HEALTH, EDUCATION, LABOR & PENSIONS** Washington, DC
*Senior Health Policy Advisor* (March 2011-December 2013)

Lead staff member on Food and Drug Administration (FDA) issues for the Senate Committee with authorizing jurisdiction over FDA.

- Played a key role in drafting and negotiating significant legislation on drug quality, drug safety, drug development, and related regulatory modernization:
  - The FDA Safety and Innovation Act of 2012, which included provisions related to pediatric research incentives, medical device approval, the safety of drug imports, expedited drug approvals, and other matters;
  - The FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, which included process changes to streamline the regulatory pathway for medical countermeasures; and
  - The Drug Quality and Security Act of 2013, which clarified the regulation of traditional compounders, created a new federal regulatory category for facilities that compound drugs outside of the traditional pharmacy setting, established a national tracking system to secure drug distribution, and raised licensure standards for pharmaceutical wholesale distributors.
- Advised Chairman Tom Harkin and Committee leadership and staff on legislative and oversight matters related to the FDA.
- Engaged with stakeholder groups during policy development, including major national organizations in the consumer and public health advocacy communities. Worked with these stakeholders to understand recommendations and refine policy proposals as appropriate to protect the public health.

**COVINGTON & BURLING LLP** Washington, DC

*Associate* (October 2005-March 2011)

Provided regulatory advice as a member of the firm's Food & Drug and Health Care practice groups. Developed deep technical expertise on a broad range of pharmaceutical law and regulatory topics.

- Advised clients on human pharmaceutical matters such as pharmaceutical advertising and promotion, Hatch-Waxman and pediatric exclusivity, bioequivalence, drug naming, and compliance programs.
- Counseled clients on health care issues including fraud and abuse risk analysis, price reporting, pharmaceutical and clinical trials reimbursement, drug coverage under the Medicare prescription drug program, and compliance with HIPAA and other medical privacy laws.
- Provided regulatory support for litigation pleadings and corporate transactions and filings.
- Pro-bono projects related to public benefits and end-of-life planning.

**UNITED STATES COURT OF APPEALS, NINTH CIRCUIT** Seattle, WA

*Law Clerk for the Hon. Richard C. Tallman* (August 2004–August 2005)

**UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA** Los Angeles, CA

*Law Clerk for the Hon. Mariana R. Pfaelzer* (August 2003–August 2004)

# Professional Activities

**PHARMACEUTICAL COMPOUNDING ADVISORY COMMITTEE (PCAC)**

*Voting Member* (November 2014-September 2016; September 2017-present)

The PCAC provides advice and recommendations to the Commissioner of the Food and Drug Administration on scientific, technical, and medical issues concerning drug compounding, including substances considered for FDA's lists of bulk substances for use in compounding, drugs that are demonstrably difficult to compound, and drugs withdrawn from the market for reasons of safety and effectiveness.

**PRESIDENTIAL ADVISORY COMMITTEE ON COMBATTING ANTIBIOTIC RESISTANT BACTERIA (PAC-CARB)**

*Liaison Member* (November 2014-September 2017)

The PAC-CARB provides advice, information, and recommendations to the Secretary of Health and Human Services regarding programs and policies intended to support and evaluate the implementation of the President's National Action Plan for Combatting Antibiotic Resistance, National Strategy for Combatting Antibiotic Resistance, and Executive Order 13676 on Combatting Antibiotic Resistant Bacteria.

**FOOD AND DRUG LAW INSTITUTE**

*Board of Directors* (January 2018- present; member since 2005)

Active member of FDLI, including past service on the Drugs and Biologics Committee, speaker at conferences and webinars, and authoring the forward for FDLI's primer on drug compounding.

# Education

**GEORGETOWN UNIVERSITY LAW CENTER**

J.D., *cum laude*

**JOHNS HOPKINS SCHOOL OF PUBLIC HEALTH**

M.P.H., concentration in Health Policy & Management

**HARVARD COLLEGE**

A.B. in Biology, *cum laude*